Literature DB >> 24863499

Clonal dissemination of extensively drug-resistant Acinetobacter baumannii producing an OXA-23 β-lactamase at a teaching hospital in Shanghai, China.

Ying Li1, Qinglan Guo1, Peng Wang2, Demei Zhu1, Xinyu Ye1, Shi Wu1, Minggui Wang3.   

Abstract

BACKGROUND/
PURPOSE: Extensively drug-resistant (XDR) Acinetobacter baumannii presents a serious therapeutic and infection control challenge. This study aimed to explore the causes for the rapid increase of XDR A. baumannii at a teaching hospital in Shanghai.
METHODS: All consecutive clinical isolates of XDR A. baumannii were collected from January to December 2010 at Huashan Hospital in Shanghai. The prevalence of carbapenemase genes was investigated by polymerase chain reaction (PCR) amplification. Genetic relatedness of the isolates was determined by enterobacterial repetitive intergenic consensus-PCR and multilocus sequence typing. A retrospective case-control study was performed for the identification of risk factors of XDR A. baumannii infections.
RESULTS: All 106 XDR A. baumannii isolates carried the blaOxA-23 gene and were resistant to all antimicrobial agents tested, except colistin, tigecycline and cefoperazone-sulbactam. One hundred and five of the strains belonged to clonal complex 92 by multilocus sequence typing, and 78 were classified as clone A1 by enterobacterial repetitive intergenic consensus-PCR. Intensive care unit residency at the time of isolation, recent general anesthesia, the number of previous antibiotic classes administered and previous hospitalization were identified as risk factors by case-control study. Efficacy rates were 62.5% (5/8), 47.4% (9/19), and 42.9% (3/7) when the XDR patients were treated with cefoperazone-sulbactam, carbapenems, or both cefoperazone-sulbactam and carbapenem, alone or in combination with other agents, respectively.
CONCLUSION: XDR A. baumannii producing OXA-23 β-lactamase was clonally disseminated at a university hospital in Shanghai. Cefoperazone-sulbactam and carbapenems alone or combined with other antibiotics may benefit XDR A. baumannii infections in the absence of other effective antibiotics.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Acinetobacter baumannii; Clonal dissemination; Extensively drug-resistant; Risk factor

Mesh:

Substances:

Year:  2014        PMID: 24863499     DOI: 10.1016/j.jmii.2014.04.005

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  10 in total

Review 1.  Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.

Authors:  Ming-Feng Lin; Chung-Yu Lan
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

2.  Acinetobacter baumannii Sequence Types Harboring Genes Encoding Aminoglycoside Modifying Enzymes and 16SrRNA Methylase; a Multicenter Study from Pakistan.

Authors:  Mohsin Khurshid; Muhammad Hidayat Rasool; Usman Ali Ashfaq; Bilal Aslam; Muhammad Waseem; Muhammad Akhtar Ali; Ahmad Almatroudi; Farhan Rasheed; Muhammad Saeed; Qinglan Guo; Minggui Wang
Journal:  Infect Drug Resist       Date:  2020-08-18       Impact factor: 4.003

3.  A locked nucleic acid (LNA)-based real-time PCR assay for the rapid detection of multiple bacterial antibiotic resistance genes directly from positive blood culture.

Authors:  Lingxiang Zhu; Dingxia Shen; Qiming Zhou; Zexia Li; Xiangdong Fang; Quan-Zhen Li
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

4.  Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality.

Authors:  Yu Jun Li; Chu Zhi Pan; Chang Quan Fang; Zhu Xiang Zhao; Hui Ling Chen; Peng Hao Guo; Zi Wen Zhao
Journal:  BMC Infect Dis       Date:  2017-05-30       Impact factor: 3.090

Review 5.  Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.

Authors:  Chang-Ro Lee; Jung Hun Lee; Moonhee Park; Kwang Seung Park; Il Kwon Bae; Young Bae Kim; Chang-Jun Cha; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293

6.  Prevalence of carbapenemases among high-level aminoglycoside-resistant Acinetobacter baumannii isolates in a university hospital in China.

Authors:  Yanhong Wang; Min Shen; Jingni Yang; Min Dai; Yaowen Chang; Chi Zhang; Guangxin Luan; Baodong Ling; Xu Jia
Journal:  Exp Ther Med       Date:  2016-10-20       Impact factor: 2.447

7.  Sulbactam Enhances in vitro Activity of β-Lactam Antibiotics Against Acinetobacter baumannii.

Authors:  Leilei Wang; Yuancheng Chen; Renru Han; Zhiwei Huang; Xuefei Zhang; Fupin Hu; Fan Yang
Journal:  Infect Drug Resist       Date:  2021-09-28       Impact factor: 4.003

8.  Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital.

Authors:  Yaowen Chang; Guangxin Luan; Ying Xu; Yanhong Wang; Min Shen; Chi Zhang; Wei Zheng; Jinwei Huang; Jingni Yang; Xu Jia; Baodong Ling
Journal:  Front Microbiol       Date:  2015-09-01       Impact factor: 5.640

9.  A multiplex loop-mediated isothermal amplification assay for rapid screening of Acinetobacter baumannii and D carbapenemase OXA-23 gene.

Authors:  Rungong Yang; Honghong Zhang; Xiaoxia Li; Ling Ye; Meiliang Gong; Jinghui Yang; Jihong Yu; Jie Bai
Journal:  Biosci Rep       Date:  2018-09-07       Impact factor: 3.840

10.  Molecular characterization and antibiotic resistance of Acinetobacter baumannii in cerebrospinal fluid and blood.

Authors:  Xiaohong Shi; Hong Wang; Xin Wang; Huaiqi Jing; Ran Duan; Shuai Qin; Dongyue Lv; Yufeng Fan; Zhenzhou Huang; Kyle Stirling; Lei Zhang; Jiazheng Wang
Journal:  PLoS One       Date:  2021-02-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.